The COMBINE project, which is part of the IMI AMR Accelerator, organised a webinar on developing target product profiles (TPPs) for antibiotics on March 15th 2024. Excellent speakers from CARB-X (Erin Duffy), Evotec (Francesca Bernardini) and GSK (Gareth Maher-Edwards) discussed TPPs in relation to aims, scope and flexibility. This public webinar was attended by more than 160 people from the AMR Accelerator and external AMR community. A panel discussion was included to allow all attendees to interact with the speakers and was focused on TPPs across the development life-cycle: from drug discovery to clinical trials, taking into account both clinical pathways, the area of application and market considerations.

Want to continue the discussion? We are planning a follow-up webinar in June on how to develop in vivo screening cascades to support a specific TPP. The webinar will focus on how to choose the right in vivo model linked to a targeted TPP and provide case studies with different examples of TPPs.

Missed the COMBINE webinar on developing TPPs for antibiotics? Watch the recording on YouTube:

About the AMR Accelerator

The aim of the Antimicrobial Resistance (AMR) Accelerator Programme is to progress the development of new medicines to treat or even prevent resistant bacterial infections in Europe and worldwide. The programme comprises the following three pillars: a Capability Building Network, a Tuberculosis Drug Development Network, and the Portfolio Building Networks. The scope of the AMR Accelerator is broad; under one structure, it addresses many of the scientific challenges of AMR, and it supports the development of new ways to prevent and treat AMR. More broadly, the AMR Accelerator contributes to the European action plan on AMR.

For more information on the AMR Accelerator, please visit


This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853967. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA companies’ in kind contribution.

About the Innovative Medicine Initiative

The Innovative Medicines Initiative (IMI) is Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations, EFPIA.

For more information on IMI, please visit


This communication reflects the views of the authors and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein.